You can only expect so much from on-line translators.
Etten Pharmaceuticals obtained the ownership of VASCEPA® Greater China in 2015 and became the marketing licensee of this product. The Phase III clinical study in China has been successfully completed by the end of 2020, and the results have very significant statistical significance. The study evaluated VASCEPA® as a treatment for patients with hypertriglyceridemia (≥500mg/dL), and reached the primary efficacy endpoint defined in the clinical trial protocol, and showed safety similar to placebo.